Nitrosamine impurity control is now a mandatory part of chemical drug quality management. This article presents a four-pillar control system covering risk assessment, limit setting, confirmatory testing, and process control. It is illustrated with N-nitroso-propranolol (NPPN) in propranolol hydrochloride tablets, where regulators set a 1,500 ng per day acceptable intake and a 240 mg per day maximum dose, producing a 6.25 ppm impurity limit.
Why Nitrosamine Impurities Forced a New Control Paradigm
Drug products are not pure substances. Impurities enter or form during production, storage, and transport, and their presence creates potential safety concerns. Genotoxic impurities are especially hazardous and must be kept strictly within limits to protect patient safety. Since 2006, international harmonization bodies and national drug regulators have issued a series of guidances on controlling genotoxic impurities.
The issue turned urgent in 2018 after trace N-nitrosodimethylamine (NDMA) showed up in valsartan active pharmaceutical ingredient. The International Agency for Research on Cancer classifies NDMA as a Group 2A carcinogen. Animal data on 228 low-molecular-weight nitrosamine derivatives show that 82 percent cause cancer in test animals through different exposure routes. International harmonization body guidance ICH M7 places nitrosamine-containing compounds in a cohort of concern and subjects them to strict oversight.
Since then, small-molecule nitrosamine impurities have turned up in many active ingredients and finished products: sartan blood pressure medicines, the ulcer medicines ranitidine and nizatidine, the diabetes medicine metformin, the tuberculosis medicines rifampin and rifabutin, and the antiviral medicine acyclovir. The response from drug regulators in China, the United States, and Europe rests on a shared principle: avoid as the priority, control as the supplement.
This background matters because nitrosamine impurity control is no longer optional for any chemical drug product. Every product with a secondary or tertiary amine in its composition needs a documented assessment.
How Regulators Frame Nitrosamine Control
Drug regulators in China, the United States, and Europe, together with Canada's health authority, have issued nitrosamine impurity control guidances covering 2020 to 2025. They adopt a universal three-step strategy: first assess the risk, second run confirmatory testing, and third take necessary control measures and update the marketing authorization. These guidances set normative requirements for how companies build nitrosamine impurity control strategies. Table 1 summarizes the key documents.
Table 1. Selected regulatory guidances on nitrosamine impurity control
Regulator | Guidance and year | Core requirement |
China's drug regulator | Nitrosamine impurity control guidance (2024) | Risk assessment and control for marketed products |
The U.S. drug regulator | Control of nitrosamine impurities in human drugs (2024) | Three-step strategy: assess, confirm, control |
The European drug regulator | Nitrosamine impurity questions and answers (2020) | Acceptable intake values set per single nitrosamine impurity |
Canada's health authority | Nitrosamine impurity guidance | Risk-based approach for active ingredients and products |
International drug-regulatory harmonization body | ICH M7 (R2) (2021) | Assessment and control of DNA-reactive impurities to limit carcinogenic risk |
The Three-Step Control Strategy
The shared regulatory strategy has three steps. Step 1 is risk assessment: determine whether a nitrosamine impurity could be present or formed in a product. Step 2 is confirmatory testing: measure the impurity with a specific, accurate, and sensitive method. Step 3 is risk-based control: where testing shows the impurity is well controlled, general process management suffices; where it is not, strict process control applies, with the test method written into quality standards and monitoring across shelf life. Results above the limit trigger an out of specification investigation.
The Four-Pillar Control System for Nitrosamine Impurity Control
The control system described here is built on four pillars: nitrosamine impurity risk assessment elements, determination of impurity limits, confirmatory testing, and process control elements. Each pillar answers a distinct question: where could the impurity come from, how much is acceptable, is the product actually below the limit, and how does manufacturing keep it there.
This four-pillar structure is the core of nitrosamine impurity control in chemical drugs, and it scales from a single active ingredient to a whole product portfolio.
Nitrosamine Formation: Mechanism and Risk Elements
Nitrosamines form when an amine reacts with a nitrosating agent. The fundamental route is nitrosation of a secondary amine by nitrous acid under acidic conditions. Nitrous acid, nitrosonium ion, and dinitrogen trioxide exist in dynamic equilibrium, so the reaction depends on pH and proceeds fastest under acidic conditions, typically pH 3 to 4. Aldehydes can catalyze nitrosation in neutral or alkaline solutions.
Five classes of active nitrosating agents are recognized: nitrosonium ion, nitrosyl halides and derivatives, alkyl nitrites, dinitrogen trioxide, and dinitrogen tetroxide. Precursors of the nitrosonium ion fall into five groups by the source of the NO group: nitrites and esters, nitrosyl halides and nitrosonium salts, nitrogen oxides, organic nitro compounds, and other reagents.
Primary amines and other compounds with an NH2 group cannot form stable nitrosamines; they degrade quickly into aryl diazonium salts or deamination products, so primary amines are not nitrosamine risk factors. Non-classical pathways also exist, including nitramine reduction, oxidation of nitrogen-containing functional groups such as hydrazones, and organometallic-mediated synthesis.
Tertiary amines with an alpha hydrogen can undergo nitrosation, though their reactivity is well below that of secondary amines. Steric hindrance around the nitrogen atom is the main factor affecting reactivity. Tertiary amines with electron-rich benzyl substituents show markedly higher reactivity. Asymmetric tertiary amines can generate multiple nitrosamine compounds, and the regioselectivity of dealkylation depends on the acidity of the reaction system.
Risk assessment comes down to three elements: the precursor amine, the nitrosating agent, and the reaction conditions. Precursor amines may come from starting materials, solvents, the active ingredient itself, or related impurities. Nitrosating agents may come from starting materials, solvents and reagents, byproducts, production water, impurities in excipients, operation units, and auxiliary operations. Finally, assess whether production pH, temperature, catalysts, and the manufacturing environment promote nitrosation. Table 2 lists the risk elements with example sources.
Table 2. Nitrosamine formation risk elements
Risk element | What to assess | Example sources |
Precursor amine | Secondary amines and tertiary amines with an alpha hydrogen | Starting materials, solvents, the active ingredient itself, related impurities |
Nitrosating agent | Nitrite, nitrogen oxides, nitro compounds | Starting materials, solvents and reagents, byproducts, production water, excipient impurities |
Reaction conditions | pH, temperature, catalysts | Acidic conditions around pH 3 to 4, heat, light, disinfectant residues |
Setting the Impurity Limit: From Acceptable Intake to PPM
For nitrosamines with positive carcinogenicity data or an actual threshold, regulators calculate the acceptable intake through linear extrapolation from the TD50, the dose that causes tumors in a quarter of test animals. Most nitrosamine impurities lack mutagenicity data. They are potent mutagenic carcinogens in the cohort of concern, so the general ICH M7 threshold of toxicological concern does not apply. The U.S. drug regulator has proposed limits for three nitrosamine impurities.
Acceptable intake values from U.S. and European regulators apply to a single nitrosamine impurity. Where several nitrosamine impurities exist, combined assessment is needed.
To get the impurity limit in parts per million, divide the acceptable intake in ng per day by the maximum daily dose in mg per day.
Impurity limit ppm = acceptable intake ng per day / maximum daily dose mg per day
Confirmatory Testing: Three Batches and Risk Tiers
In active pharmaceutical ingredient process research, an avoid-control-remove strategy minimizes genotoxic impurity carryover into the final product. ICH M7 describes four control approaches for genotoxic impurities in APIs, but current U.S. and European nitrosamine guidances do not adopt Method 4, under which testing is waived when process parameters assure levels below the acceptable limit. They recommend confirmatory testing to demonstrate that control is justified.
After setting the acceptable intake, establish a specific, accurate, and sensitive test method for confirmatory testing, and understand the factors affecting impurity formation from material properties, production process, and production environment. Regulators recommend testing at least three representative batches, chosen with a deep understanding of nitrosamine-forming factors and good process control. If results vary widely, or for post-market risk monitoring and retrospective analysis, increase the number of batches tested.
The risk tier depends on the result. If all three batches test below 10 percent of the limit, apply a low-risk strategy: general process control, with process parameters established and validated based on nitrosamine-forming factors; the test method and limits need not be written into quality standards. If results cannot reliably stay below 10 percent of the limit, apply a medium-to-high risk strategy: strict process control, validated parameter ranges, the test method in quality standards, and monitoring through shelf life. If any result exceeds the limit, open an out of specification investigation, study the root cause, and implement corrective changes where needed. Table 3 shows the tiers.
Table 3. Risk control tiers from confirmatory testing
Test result | Risk tier | Control approach |
All three batches below 10 percent of limit | Low risk | General process control; test method and limits not required in quality standards |
Results not reliably below 10 percent of limit | Medium-to-high risk | Strict process control; test method in quality standards; monitor through shelf life |
Any result above the limit | Confirmed exceedance | Out of specification investigation; root cause and corrective action |
Process Control Elements: API and Finished Formulation
For active ingredients, control centers on three areas. First, control material quality: starting materials, intermediates, and solvents may carry residual secondary amines or nitrosating agents; review production water purification and the effects of activated carbon, audit the supply chain, and set acceptance standards. Second, optimize the process: during route development, minimize or prevent nitrosamine formation by avoiding precursor amines and nitrosating agents, or materials containing them. A classic example is NDMA in valsartan, formed when sodium azide quenching reacted with trace dimethylamine in the DMF solvent. Third, understand factors affecting impurity formation.
For finished formulations, control spans six areas: accepting raw materials, auditing excipient suppliers, and more. Excipients can introduce nitrosamines directly. Even trace parts-per-million nitrates in excipients can generate nitrosamines, and nitrate levels vary widely between excipients and batches depending on raw material sources and processing steps such as titration, oxidation, and bleaching. Common excipient impurities such as peroxides and formaldehyde can also promote nitrosamine formation.
Case Study: NPPN in Propranolol Hydrochloride Tablets
The control system was applied to a 2024 national drug sampling special item on genotoxic impurities, focusing on N-nitroso-propranolol (NPPN) in propranolol hydrochloride tablets. The sections below dissect the NPPN risk assessment and explain the resulting control strategy.
Risk Factors Behind NPPN in Propranolol Tablets
A fishbone analysis examined raw materials, excipients, production process, packaging materials, and production environment for routes by which precursor amines and nitrosating agents enter, and for process steps that promote nitrosation. Four risk factors emerged. First, propranolol active ingredient contains a secondary amine structure and readily forms nitrosamine impurities. Second, production water and excipients may contain trace nitrates. Third, wet granulation and fluidized drying may promote nitrosation. Fourth, residual ozone from environmental disinfection promotes nitrosation. Therefore, NPPN formation risk in propranolol hydrochloride tablets was confirmed.
The NPPN Limit: 1,500 ng Acceptable Intake and 6.25 PPM
U.S. and European regulators set the acceptable intake for NPPN at 1,500 ng per day based on carcinogenic potency classification. The propranolol hydrochloride tablet label gives a maximum daily dose of 240 mg. Applying the formula gives an impurity limit of 6.25 ppm.
What the 77-Batch Sampling Showed
Seventy-seven batches were sampled from six companies: Company A 15 batches, Company B 10, Company C 18, Company D 12, Company E 8, and Company F 14. Twelve near-expiry batches and ten active ingredient batches were also collected. An HPLC-MS/MS method (high performance liquid chromatography tandem mass spectrometry) was established for NPPN measurement, and samples were tested at a 30 percent monitoring ratio.
Company C had one batch above the proposed limit in initial testing, so its samples received full monitoring. Across all 77 batches from six companies, only Company C had batches above the proposed limit: two of them. Every other company stayed below. However, most results were above 10 percent of the limit, so a medium-to-high risk control strategy applied, with the test method written into quality standards. Table 4 shows the results.
Table 4. NPPN sampling results by company
Company | Sampled batches | Batches above 6.25 ppm limit |
Company A | 15 | 0 |
Company B | 10 | 0 |
Company C | 18 | 2 |
Company D | 12 | 0 |
Company E | 8 | 0 |
Company F | 14 | 0 |
Total | 77 | 2 |
Statistical comparison across companies used the Kruskal-Wallis test, which showed significant differences between groups (alpha 0.05, P equals 0.001). Pairwise comparison with Bonferroni correction found NPPN levels in Company C samples significantly higher than the other five companies, with no significant differences among the other five. Company C products therefore carry formulation-process risk, warranting out of specification investigation, root-cause analysis, and corrective measures where necessary.
Moisture, Heat, and Light: What Drove NPPN Formation
The study examined four drivers of NPPN formation: raw material introduction, excipient effects, process conditions, and storage.
Raw materials: Ten active ingredient batches were tested for NPPN. All were below 0.2 ppm, far lower than levels in finished products, so raw material introduction was a low risk.
Excipients: Nitrate testing found nitrates in dextrin, stearic acid, and hydroxypropyl methylcellulose; other excipients were below the 0.05 ppm detection limit. Compatibility testing mixed the active ingredient with each excipient at formula ratios and held samples at 60 to 62 degrees Celsius and 40 to 50 percent relative humidity for 10 days. NPPN increased significantly in calcium hydrogen phosphate, noticeably in dextrin and stearic acid, and slightly in mannitol; other excipients showed no clear change.
Calcium hydrogen phosphate loses weight under these conditions because it contains two molecules of crystal water; heat releases the water, which accelerates NPPN formation. A second compatibility test at 60 to 62 degrees Celsius and 70 to 80 percent relative humidity showed generally higher NPPN across samples, while the calcium hydrogen phosphate increase was smaller than for dextrin, gelatin, and sucrose, the more hygroscopic excipients. Moisture is an important driver of NPPN formation. Table 5 summarizes the compatibility results.
Table 5. Excipient compatibility and NPPN change
Excipient | Nitrate detected | NPPN change after compatibility testing |
Calcium hydrogen phosphate | Not reported | Significant increase |
Dextrin | Yes | Noticeable increase |
Stearic acid | Yes | Noticeable increase |
Mannitol | No | Slight increase |
Other excipients | No | No obvious change |
Process: High temperature and light both raised NPPN detection. Manufacturers should focus on temperature and humidity during wet granulation and tableting, and on temperature, humidity, and light control during material transfer and storage.
Storage: Accelerated stability testing at 40 to 42 degrees Celsius and 70 to 80 percent relative humidity showed NPPN slowly rising in samples from all companies. Packaging materials should therefore provide thermal insulation.
Control Measures Drawn from the Propranolol Study
Based on the findings, the study proposes three control measures. First, screen formulations and strengthen excipient supplier audits. Second, optimize production processes and strengthen process control, especially temperature and humidity in wet granulation and tableting. Third, optimize packaging and select packaging materials with good insulation properties. Table 6 lists the measures by risk source.
Table 6. Control measures by risk source
Risk source | Control measure |
Raw material introduction | Screen formulations; audit excipient suppliers |
Process conditions | Optimize wet granulation and tableting; control temperature and humidity |
Packaging | Select packaging materials with thermal insulation |
Limitations
The assessment elements and control elements in this system may change as research into nitrosamine formation mechanisms advances. The study relied on literature review and sampling data; product-specific limits and controls still require manufacturer-specific verification.
Bottom line
Nitrosamine impurity control in chemical drugs works best as a four-pillar system: assess where the impurity could arise, set a science-based limit, confirm with representative-batch testing, and control through process and packaging measures. The propranolol case shows the system in action: a 6.25 ppm NPPN limit derived from a 1,500 ng per day acceptable intake, two non-compliant batches traced to one manufacturer, and moisture identified as a key driver. Risk-based nitrosamine impurity control lets regulators and companies target resources where nitrosamine risk is real.
FAQ
What is a nitrosamine impurity and why is it a concern?
Nitrosamines are compounds containing the nitroso group. Many are potent mutagenic carcinogens, and animal data show most tested derivatives cause cancer through different exposure routes. Regulators list nitrosamines as a cohort of concern and require strict control in drug products. Because patients may take a medicine daily for years, cumulative exposure must stay below an established acceptable intake.
How do nitrosamines form in drug products?
They form when a secondary amine or certain tertiary amines react with a nitrosating agent. The common route is reaction with nitrous acid under acidic conditions, typically at pH 3 to 4. Sources include residual amines in raw materials or solvents, nitrite in water or excipients, and process conditions such as heat, light, or disinfectant residues that promote the reaction.
Which drug products face the highest nitrosamine risk?
Products whose active ingredient or excipients contain secondary or tertiary amines face higher risk. Sartan blood pressure medicines, ranitidine, nizatidine, metformin, and some antivirals have shown nitrosamine contamination. Risk also rises when manufacturing uses nitrite-containing materials, acidic process steps, or packaging that does not protect against moisture and heat.
How is the acceptable intake for a nitrosamine impurity determined?
For nitrosamines with positive carcinogenicity data, regulators derive the acceptable intake through linear extrapolation from the TD50, the dose causing tumors in 25 percent of test animals. Most nitrosamine impurities lack mutagenicity data and are treated as potent mutagenic carcinogens, so the general ICH M7 threshold approach does not apply and compound-specific limits are used instead.
How do you convert acceptable intake into a ppm limit?
Divide the acceptable intake in ng per day by the maximum daily dose in mg per day. The result is the impurity limit in parts per million. For propranolol hydrochloride tablets, a 1,500 ng per day acceptable intake divided by a 240 mg per day maximum dose gives a limit of 6.25 ppm.
How many batches should be tested for confirmatory testing?
Regulators recommend testing at least three representative batches. Batch selection should rest on a deep understanding of nitrosamine-forming factors and good process control. If results vary widely or the product is already on the market, more batches should be tested to make the assessment reliable.
When does a drug product need strict process control for nitrosamines?
When test results cannot be reliably kept below 10 percent of the limit, the product needs strict process control. The manufacturer must define process parameter ranges, execute process rules strictly, list the test method in quality standards, and monitor throughout shelf life. Results above the limit trigger an out of specification investigation.
What drove NPPN formation in propranolol hydrochloride tablets?
The propranolol active ingredient contains a secondary amine structure, so it can form nitrosamines. Trace nitrates may enter through production water or excipients. Wet granulation and fluidized drying promote the nitrosation reaction. Residual ozone from environmental disinfection also promotes nitrosation, and moisture released from excipients such as calcium hydrogen phosphate accelerates impurity formation.
What was the NPPN limit for propranolol hydrochloride tablets?
Regulators set the acceptable intake for N-nitroso-propranolol at 1,500 ng per day. With a maximum daily dose of 240 mg, the calculated impurity limit is 6.25 ppm. This limit guided the confirmatory testing and risk classification of the sampled products.
How did different manufacturers compare in the 77-batch sampling?
Seventy-seven batches from six companies were sampled. Two batches exceeded the 6.25 ppm limit, both from Company C. Statistical testing showed Company C results were significantly higher than the other five companies, while the other five showed no significant differences. Most results were above 10 percent of the limit, so a medium-to-high risk control strategy applied.
What control measures reduce nitrosamine risk in tablets?
Measures include screening the formulation and auditing excipient suppliers, optimizing wet granulation and tableting with tighter temperature and humidity control, and selecting packaging materials with good thermal insulation. The study also found raw material introduction to be a low risk, since NPPN in raw materials was below 0.2 ppm.
Can excipients introduce nitrosamine risk into a tablet formulation?
Yes. The study detected nitrates in dextrin, stearic acid, and hydroxypropyl methylcellulose. Compatibility testing showed NPPN increased significantly with calcium hydrogen phosphate, which releases crystal water at 60 degrees Celsius, and noticeably with dextrin and stearic acid. Moisture was confirmed as a key driver of nitrosamine formation.